Manufacturer with High Quality
Commercial Supply Ambrisentan (CAS: 177036-94-1) Related Intermediates:
3,3-Diphenyloxirane-2-carboxylic Acid Methyl Ester CAS: 76527-25-8
Methyl 2-hydroxy-3-methoxy-3,3-diphenylpropanoate CAS: 178306-47-3
2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS: 178306-51-9
(S)-2-Hydroxy-3-methoxy-3,3-diphenylpropionic Acid CAS: 178306-52-0
L-Proline Methyl Ester Hydrochlorid CAS: 2133-40-6
4,6-Dimethyl-2-(methylsulfonyl)pyrimidine CAS: 35144-22-0
| Chemical Name |
2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid |
| Synonyms |
Ambrisentan PI-2 |
| CAS Number |
178306-51-9 |
| CAT Number |
RF-PI161 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C16H16O4 |
| Molecular Weight |
272.3 |
| Density |
1.248 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Powder |
| Purity |
≥98.5% (HPLC) |
| Moisture (K.F) |
≤1.0% |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Ambrisentan (CAS: 177036-94-1) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS: 178306-51-9 Intermediate of Ambrisentan (CAS: 177036-94-1) in the treatment of Pulmonary Arterial Hypertension (PAH).
Ambrisentan (CAS: 177036-94-1) is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. It is the third ET-receptor antagonist to be marketed for this indication behind bosentan and sitaxsentan. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation ofETA and ETB receptors.
Ambrisentan (CAS: 177036-94-1), (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid(Letairis), is a potent ETA selective endothelin antagonist that,is indicated, in the treatment of pulmonary arterial hypertension(PAH). PAH is a rare disease that if left untreated has ahigh mortality rate. In June of 2007, the FDA granted approvalof Ambrisentan (CAS: 177036-94-1) for once-daily treatment of PAH. Studies have shown that it improves a 6-minute walk by about30 to 60 m for patients receiving placebo.